单核细胞趋化蛋白受体的研究进展

单核细胞趋化蛋白及其受体在机体免疫应答中(免疫调节、器官形成、调节造血和神经元通讯)发挥了重要作用,同时也广泛参与某些疾病的发病机制(动脉粥样硬化、感染炎症性疾病及肿瘤等)。因此,有关趋化性细胞因子的新理论和技术可为临床治疗某些疾病提供了新思路。本文简要地综述单核细胞趋化蛋白受体的生物学特性、生物学作用及对心血管疾病的影响作用。     

人单核细胞趋化蛋白—1的研究进展

人单核细胞趋化蛋白－１为一由７６个氨基酸组成的单肽链,它既具有特异的单核细胞趋化活性,也具有激活单核细胞的活性,在机体防御,炎症恢复和抗肿瘤等方面起着重要作用。本就ＭＣＰ－１近几年来的研究进展作一综述。     

单核细胞趋化蛋白-1与2型糖尿病大血管病变

单核细胞趋化蛋白-1(monocyte chemoattractant protein-1;MCP-1)属于炎症趋化因子CC亚族成员,它能趋化T淋巴细胞、单核细胞,诱导内皮细胞、单核细胞释放黏附因子,使单核/巨噬细胞向病变处聚集。这些免疫及炎症过程有可能导致2型糖尿病大血管病变的发生、发展。本文就单核细胞趋化蛋白-1促使动脉粥样硬化的机制、及其干预治疗,单核细胞趋化蛋白-1表达上调的影响因素,深入了解单核细胞趋化蛋白-1与2型糖尿病大血管病变的关系。     

单核细胞趋化蛋白1及其受体CCR2mRNA在急性酒精中毒大鼠脑组织的表达

目的:观察大鼠急性酒精中毒后脑组织趋化因子单核细胞趋化蛋白1(MCP-1)及其受体CCR2mRNA水平的表达变化.方法:制备急性酒精中毒模型,用SYBR Green I荧光实时定量PCR技术动态定量监测脑组织中MCP-1与CCR2 mRNA在急性酒精中毒后不同时间点表达的变化.结果:息性酒精中毒后6h脑组织MCP-1 ...     

单核细胞趋化蛋白-1在糖尿病肾病中的作用

糖尿病肾病是多因素引起的复杂性疾病,近年研究发现炎症反应参与了该病的发生与发展.单核细胞趋化蛋白-1是趋化因子CC亚家族的一员,在募集巨噬细胞等炎性细胞参与炎症反应中扮演着重要的角色.其趋化单核巨噬细胞于糖尿病肾组织中,可介导溶酶体释放,产生氧自由基,促进单核巨噬细胞表达β1-转化生长因子(transforming growth factor β1,TGF-β1),而广泛浸润臣噬细胞加剧了肾小球基底膜增厚、细胞外基质堆积,进而发展为肾小球硬化和间质纤维化.深入研究单核细胞趋化蛋白-1在糖尿病肾病中的作用,可望为糖尿病肾病的预防和治疗提供新的思路和途径.     

剪切力对单核细胞趋化蛋白-1的影响

单核细胞趋化蛋白-1（MCP-1）能趋化单核细胞在内皮细胞下聚集,是动脉粥样硬化最早期的病理改变之一.从生物力学的角度对体外培养的人脐静脉内皮细胞（HUVEC）合成和分泌MCP-1的规律作了研究.通过流动小室,HUVEC给予0.4,1.0, 2.0 N/m²的剪应力,运用免疫组化,图象处理及ELISA方法测出不同时间胞浆及灌流液中MCP-1的含量,结果表明HUVEC合成和分泌MCP-1是随剪切力和时间变化而变化的.该工作为进一步理解剪切力诱导动脉粥样硬化的发生提供实验数据.     

以融合蛋白形式在大肠杆菌中表达人MCP—1

将编码人单核细胞趋化蛋白－１（ＭＣＰ－１）的基因亚克隆到大肠杆菌表达载体ｐＥＸ３１Ａ中,在大肠杆菌中表达出ＭＳ２／ＭＣＰ－１融合蛋白,该表达产物约占菌体总蛋白的１５％左右,Ｗｅｓｔｅｒｎ ｂｌｏｔ检测表明,表达产物可与ＭＣＰ－１抗体特异反应,采用琼脂糖平板法进行活性测定表明,表达产物具有明显的单核细胞趋化活性,说明Ｎ端融合一段细菌蛋白对ＭＣＰ－１有无趋化活性可能没有影响。     

MCP-1及其在相关疾病中的治疗措施

单核细胞趋化蛋白1(MCP-1)属于趋化因子的CC亚家族,MCP-1与其受体CCR2相结合,参与了多种炎性疾病的发生。该从抑制MCP-1的表达、MCP-1的拮抗剂、CCR2的拮抗剂、DNA疫苗几方面综述了针对MCP-1的治疗措施。     

单核细胞趋化蛋白-1、高迁移率族蛋白B1与溃疡性结肠炎患者肠道菌群变化的相关性

目的 探讨单核细胞趋化蛋白-1（MCP-1）、高迁移率族蛋白B1（HMGB1）与溃疡性结肠炎（UC）患者肠道菌群变化的相关性。方法 选取2016年9月‒2018年1月遂宁市中心医院收治的98例UC患者资料,根据Mayo评分系统将UC患者分为活动期组（n=50）和缓解期组（n=48）。选取同期进行体检的健康人50例作为对照组。比较各组间肠道菌群,血清MCP-1、HMGB1水平,并进行Pearson相关分析。结果 活动期组患者肠道乳杆菌、双歧杆菌含量[（5.34±0.87）、（5.81±0.83）CFU/g]显著低于缓解期组和对照组[（8.07±0.86）、（8.35±0.88）CFU/g;（8.13±0.91）、（8.46±0.95）CFU/g]（F=12.035,P0.05）。活动期组和缓解期组患者血清MCP-1、HMGB1水平[（267.42±23.51）、（21.35±2.26）ng/mL;（188.15±20.73）、（6.28±1.38）ng/mL]显著高于对照组[（106.38±15.92）、（2.13±0.41）ng/mL]（F=84.163,P<0.001;F=25.386,P<0.001）;活动期组患者血清MCP-1、HMGB1水平[（267.42±23.51）、（21.35±2.26）ng/mL]显著高于缓解期组[（188.15±20.73）、（6.28±1.38）ng/mL]（t=17.676、39.641,均P<0.05）。经过Pearson相关性分析,MCP-1、HMGB1与UC患者乳杆菌、双歧杆菌含量呈负相关（r=‒0.715、‒0.659,r=‒0.703、‒0.614,均P<0.001）,与大肠埃希菌、肠球菌、拟杆菌含量呈正相关（r=0.783、0.702,r=0.762、0.735,r=0.653、0.612,均P<0.001）。结论 MCP-1、HMGB1作为促炎因子可介导肠黏膜炎性反应,引起UC患者肠道菌群的紊乱。     

单核细胞趋化蛋白-1诱导人脐静脉内皮细胞凋亡的分子机制(英文)

本研究旨在探讨单核细胞趋化蛋白-1(monocyte chemotacitic protein-1,MCP-1)诱导人脐静脉内皮细胞(human umbilical vein endothelial cells,hUVECs)凋亡的分子机制。胶原酶消化收集hUVECs,体外培养细胞,用胰蛋白酶-EDTA混合液消化传代,用血管性假血友病因子(von Willebrand factor,vWF)和VEGF受体2(KDR)免疫染色证实培养细胞为内皮细胞;用不同浓度MCP-1(0.1、1.0、10、100ng/mL)分别作用hUVECs24h、48h;用流式细胞术及蛋白免疫印迹法检测凋亡相关蛋白Fas、Bcl-2、Bax的表达。如我们前期结果所示,MCP-1能诱导hUVECs的凋亡,其效应随浓度和时间的增加而增强;与对照组比较,MCP-1下调抑凋亡蛋白Bcl-2的表达,上调促凋亡蛋白Fas、Bax的表达。以上结果表明,MCP-1能诱导hUVECs凋亡,其作用机制可能与上调Bax、Fas蛋白及下调Bcl-2蛋白表达有关。     

Identification of New Regulatory Sequences Far Upstream of the Mouse Monocyte Chemoattractant Protein-1 Gene

We systematically searched for sequences influencing the expression of the mouse monocyte chemoattractant protein-1 (MCP-1) gene (Scya2) by mapping DNase I hypersensitive sites (HS) in the chromatin of mesangial cells in a 40-kb interval around the gene. We found nine HS located between -24 kb and +12.7 kb. Three HS coincided with previously known regulatory sequences (HS-2.4, HS-1.0, and HS-0.2). We tested two of the previously unknown HS located far upstream of Scya2 (HS-19.4 and HS-16.3) in transfection experiments using luciferase reporter constructs and mouse mesangial cells as recipients. In transient transfections, both HS had a moderate effect on basal promoter activity as well as promoter activity stimulated by tumor necrosis factor-alpha. In stable transfection experiments, we found much higher activity. A DNA fragment containing HS-19.4 and HS-16.3 caused a considerable increase in the number of stably integrated luciferase copies. We determined the nucleotide sequence of the 5' flanking region to -28.6 kb. Computer-assisted sequence analysis did not yield evidence of an additional gene. These HS are located within the 5' flanking region of a gene cluster consisting of Scya2 (MCP-1), Scya7 (MCP-3), Scya11 (eotaxin), Scya12 (MCP-5), and Scya8 (MCP-2). This report represents the first comprehensive chromatin analysis of the mouse MCP-1 locus leading to the identification of a complex regulatory region located far upstream of Scya2.     

Urinary Concentration of Monocyte Chemoattractant Protein-1 in Idiopathic Glomerulonephritis: A Long-Term Follow-Up Study

Background

Monocyte chemoattractant protein-1 (MCP-1), which is up regulated in kidney diseases, is considered a marker of kidney inflammation. We examined the value of urine MCP-1 in predicting the outcome in idiopathic glomerulonephritis.

Methods

Between 1993 and 2004, 165 patients (68 females) diagnosed with idiopathic proteinuric glomerulopathy and with serum creatinine <150 µmol/L at diagnosis were selected for the study. Urine concentrations of MCP-1 were analyzed by ELISA in early morning spot urine samples collected on the day of the diagnostic kidney biopsy. The patients were followed until 2009. The progression rate to end-stage kidney disease was calculated using Kaplan–Meier survival analysis. End-stage kidney disease (ESKD) was defined as the start of kidney replacement therapy during the study follow-up time.

Results

Patients with proliferative glomerulonephritis had significantly higher urinary MCP-1 excretion levels than those with non-proliferative glomerulonephritis (p<0.001). The percentage of patients whose kidney function deteriorated significantly was 39.0% in the high MCP-1 excretion group and 29.9% in the low MCP-1 excretion group. However, after adjustment for confounding variables such as glomerular filtration rate (GFR) and proteinuria, there was no significant association between urine MCP-1 concentration and progression to ESKD, (HR = 1.75, 95% CI = 0.64–4.75, p = 0.27).

Conclusion

Our findings indicate that progression to end-stage kidney disease in patients with idiopathic glomerulopathies is not associated with urine MCP-1 concentrations at the time of diagnosis.     

Identification of Serum Monocyte Chemoattractant Protein-1 and Prolactin as Potential Tumor Markers in Hepatocellular Carcinoma

Early diagnosis of hepatocellullar carcinoma (HCC) remains a challenge. The current practice of serum alpha-fetoprotein (AFP) measurement is inadequate. Here we utilized a proteomic approach to identify novel serum biomarkers for distinguishing HCC patients from non-cancer controls. We profiled the serum proteins in a group of 58 resectable HCC patients and 11 non-HCC chronic hepatitis B (HBV) carrier samples from the Singapore General Hospital (SGH) using the RayBio® L-Series 507 Antibody Array and found 113 serum markers that were significantly modulated between HCC and control groups. Selected potential biomarkers from this list were quantified using a multiplex sandwich enzyme-linked immunosorbent assay (ELISA) array in an expanded SGH cohort (126 resectable HCC patients and 115 non-HCC chronic HBV carriers (NC group)), confirming that serum prolactin and monocyte chemoattractant protein-1 (MCP-1) were significantly upregulated in HCC patients. This finding of serum MCP-1 elevation in HCC patients was validated in a separate cohort of serum samples from the Mochtar Riady Institute for Nanotechnology, Indonesia (98 resectable HCC, 101 chronic hepatitis B patients and 100 asymptomatic HBV/HCV carriers) by sandwich ELISA. MCP-1 and prolactin levels were found to correlate with AFP, while MCP-1 also correlated with disease stage. Subsequent receiver operating characteristic (ROC) analysis of AFP, prolactin and MCP-1 in the SGH cohort and comparing their area under the ROC curve (AUC) indicated that neither prolactin nor MCP-1 on their own performed better than AFP. However, the combination of AFP+MCP-1 (AUC, 0.974) had significantly superior discriminative ability than AFP alone (AUC, 0.942; p<0.001). In conclusion, prolactin and MCP-1 are overexpressed in HCC and are conveniently quantifiable in patients’ sera by ELISA. MCP-1 appears to be a promising complementary biomarker for HCC diagnosis and this MCP-1+AFP model should be further evaluated as potential biomarker on a larger scale in patients at-risk of HCC.     

Monocyte Chemoattractant Protein-1 Deficiency Attenuates Oxidative Stress and Protects against Ovariectomy-Induced Chronic Inflammation in Mice

Background

Loss of ovarian function is highly associated with an elevated risk of metabolic disease. Monocyte chemoattractant protein-1 (MCP-1, C-C chemokine ligand 2) plays critical roles in the development of inflammation, but its role in ovariectomy (OVX)-induced metabolic disturbance has not been known.

Methodology and Principal Findings

We investigated the role of MCP-1 in OVX-induced metabolic perturbation using MCP-1-knockout mice. OVX increased fat mass, serum levels of MCP-1, macrophage-colony stimulating factor (M-CSF), and reactive oxygen species (ROS), whereas MCP-1 deficiency attenuated these. OVX-induced increases of visceral fat resulted in elevated levels of highly inflammatory CD11c-expressing cells as well as other immune cells in adipose tissue, whereas a lack of MCP-1 significantly reduced all of these levels. MCP-1 deficiency attenuated activation of phospholipase Cγ2, transforming oncogene from Ak strain, and extracellular signal-regulated kinase as well as generation of ROS, which is required for up-regulating CD11c expression upon M-CSF stimulation in bone marrow-derived macrophages.

Conclusions/Significance

Our data suggested that MCP-1 plays a key role in developing metabolic perturbation caused by a loss of ovarian functions through elevating CD11c expression via ROS generation.     

沉默单核细胞趋化蛋白-1基因降低人食管癌EC109细胞的迁移及侵袭能力

单核细胞趋化蛋白-1(monocyte chemoattractant protein-1,MCP-1)是白色脂肪细胞分泌的炎症趋化刺激因子,属于趋化因子CC亚族,可促进肿瘤血管形成和细胞外基质降解,从而促进肿瘤细胞的浸润与转移。沉默MCP-1基因可显著抑制恶性肿瘤生长及转移,但其作用的分子机制尚不完全清楚。本研究应用小干扰RNA技术沉默人食管癌EC109细胞中MCP-1表达。细胞划痕试验显示,与对照组相比,沉默MCP-1基因可明显抑制食管癌EC109细胞迁移能力。Transwell 侵袭实验显示,沉默MCP-1基因后,EC109细胞侵袭能力降低。Western 印迹试验和RT-PCR试验揭示,沉默MCP-1基因后,细胞中MMP-7、MMP-9、TGF-β1及VEGF表达水平显著下降。研究结果提示,沉默MCP-1基因可通过抑制MMP-7、MMP-9、TGF-β1及VEGF表达,降低癌细胞迁移及侵袭能力。     

正义、反义MCP-1基因逆转录病毒载体重组质粒的构建和包装

为构建含单核细胞趋化蛋白-1(Monocytechemoattractantprotein-1,MCP-1)基因的重组逆转录病毒pLXSN/MCP-1质粒.用RT-PCR技术从大鼠系膜细胞中扩增出MCP-1全长DNA,将其与Pgem-TE连接,用限制性内切酶EcoRⅠ对pTE-MCP-1和逆转录病毒质粒pLXSN分别进行酶切.在T4连接酶的作用下,构建重组逆转录病毒质粒pLXSN/MCP-1.经BglⅡ,XhoⅠ酶切鉴定MCP-1在质粒中的方向,用脂质体介导的方法把重组质粒DNA转染进入包装细胞PA317中,经过G418筛选出抗性克隆.通过NIH3T3细胞测定病毒液的病毒滴度.结果证实经过RT-PCR技术从大鼠系膜细胞中扩增出MCP-1全长DNA与所需的大小一致.重组质粒经酶切分析与预期的结果一致.G418筛选出抗性克隆,能稳定合成并分泌重组逆转录病毒颗粒.NIH3T3细4胞测定病毒滴度为17×10cfu/mL.     

Serum Levels of Monocyte Chemoattractant Protein-1 and All-Cause and Cardiovascular Mortality among Patients with Coronary Artery Disease

Background

Monocyte chemoattractant protein-1 (MCP-1) is an important chemokine at multiple phases of atherosclerosis in animals, but human studies are few and inconsistent. The aim of this study is to investigate the association of serum MCP-1with all-cause and cardiovascular disease (CVD) mortality among coronary artery disease (CAD) patients and determine whether this biomarker can add secondary prognostic value to standard risk predictors.

Methods

MCP-1 was measured at baseline in 1411 CAD patients who were 40–85 years of age. Cox proportional hazards regression models were used to estimate the association of MCP-1 levels with death risk.

Results

During a median follow-up of 3.3 years, 117 deaths were recorded, 88 of which were due to CVD. The multivariable-adjusted hazard ratios across tertiles of MCP-1 were 1.51 (95% confidence intervals [CI] 0.89–2.58), 1.00, and 2.11 (95% CI 1.31–3.40) for all-cause mortality, and 1.50 (95% CI 0.80–2.81), 1.00, and 2.21 (95% CI 1.27–3.87) for CVD mortality. The addition of serum MCP-1 to the fully adjusted model increased the C-index by 0.009 (p<0.0001) for all-cause mortality and 0.008 (p<0.0001) for CVD mortality and significantly improved the predictive ability by 12.1% (P = 0.006) on all-cause mortality and 12.6% (P = 0.003) on CVD mortality using the net reclassification improvement method.

Conclusions

Both lower and higher MCP-1 levels are associated with an increased risk of all-cause and CVD mortality among CAD patients. More research is needed to confirm its clinical relevance.     

The Therapeutic Role of Monocyte Chemoattractant Protein-1 in a Renal Tissue Engineering Strategy for Diabetic Patients

In this study we aim to boost the functional output of the intra-kidney islet transplantation for diabetic patients using a tissue engineered polymeric scaffold. This highly porous electrospun scaffold featured randomly distributed fibers composed of polycaprolactone (PCL) and poliglecaprone (PGC). It successfully sustained murine islets in vitro for up to 4 weeks without detected cytotoxicity. The in vivo study showed that the islet population proliferated by 89% within 12 weeks when they were delivered by the scaffold but only 18% if freely injected. Correspondingly, the islet population delivered by the scaffold unleashed a greater capability to produce insulin that in turn further drove down the blood glucose within 12 weeks after the surgery. Islets delivered by the scaffold most effectively prevented diabetic deterioration of kidney as evidenced by the lack of a kidney or glomerular enlargement and physiological levels of creatinine, urea nitrogen and albumin through week 12 after the surgery. Unlike traditional wisdom in diabetic research, the mechanistic study suggested that monocytes chemoattractant protein-1 (MCP-1) was responsible for the improved preservation of renal functions. This study revealed a therapeutic role of MCP-1 in rescuing kidneys in diabetic patients, which can be integrated into a tissue engineered scaffold to simultaneously preserved renal functions and islet transplantation efficacy. Also, this study affords a simple yet effective solution to improve the clinical output of islet transplantation.     

Deficiency for the Chemokine Monocyte Chemoattractant Protein-1 Aggravates Tubular Damage after Renal Ischemia/Reperfusion Injury

Temporal expression of chemokines is a crucial factor in the regulation of renal ischemia/reperfusion (I/R) injury and repair. Beside their role in the migration and activation of inflammatory cells to sites of injury, chemokines are also involved in other processes such as angiogenesis, development and migration of stem cells. In the present study we investigated the role of the chemokine MCP-1 (monocyte chemoattractant protein-1 or CCL2), the main chemoattractant for monocytes, during renal I/R injury. MCP-1 expression peaks several days after inducing renal I/R injury coinciding with macrophage accumulation. However, MCP-1 deficient mice had a significant decreased survival and increased renal damage within the first two days, i.e. the acute inflammatory response, after renal I/R injury with no evidence of altered macrophage accumulation. Kidneys and primary tubular epithelial cells from MCP-1 deficient mice showed increased apoptosis after ischemia. Taken together, MCP-1 protects the kidney during the acute inflammatory response following renal I/R injury.